318 related articles for article (PubMed ID: 33529489)
1. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
Punekar YS; Parks D; Joshi M; Kaur S; Evitt L; Chounta V; Radford M; Jha D; Ferrante S; Sharma S; Van Wyk J; de Ruiter A
HIV Med; 2021 Jul; 22(6):423-433. PubMed ID: 33529489
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Lagi F; Giacomelli A; Borghi V; Ciccullo A; Taramasso L; Madeddu G; D'Ettorre G; Giacometti A; Ducci F; De Vito A; Pincino R; Di Giambenedetto S; Mussini C; Antinori S; Sterrantino G
J Med Virol; 2023 Oct; 95(10):e29149. PubMed ID: 37805832
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R; Yombi JC; Darcis G; Florence E; Allard SD; De Scheerder MA; Henrard S; Demeester R; Messiaen P; Ausselet N; Loeckx M; Delforge M; De Wit S;
HIV Med; 2023 Mar; 24(3):267-278. PubMed ID: 35938381
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.
Ramos-Ruperto L; Arcos-Rueda MDM; de Miguel-Buckley R; Busca-Arenzana C; Mican R; Montejano R; Delgado-Hierro A; Montes ML; Valencia ME; Serrano L; Arribas JR; González J; Bernardino JI; Martín-Carbonero L
HIV Med; 2024 Jun; 25(6):684-691. PubMed ID: 38379338
[TBL] [Abstract][Full Text] [Related]
7. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY
Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir-Based Dual Therapies in HIV Pretreated Patients: A Real-Life Study in Madrid.
Amor-García MÁ; Rodríguez-González CG; Chamorro-de-Vega E; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2022 Apr; 56(4):401-411. PubMed ID: 34382435
[TBL] [Abstract][Full Text] [Related]
10. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY
Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
14. Real world use of dolutegravir two drug regimens.
Bowman C; Ambrose A; Kanitkar T; Flores K; Simoes P; Hart J; Hunter A; Akodu J; Barber TJ
AIDS; 2023 Apr; 37(5):785-788. PubMed ID: 36728219
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
Butler K; Anderson SJ; Hayward O; Jacob I; Punekar YS; Evitt LA; Oglesby A
J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564
[No Abstract] [Full Text] [Related]
16. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
Suárez-García I; Alejos B; Ruiz-Algueró M; García Yubero C; Moreno C; Bernal E; Pérez-Is L; Zubero Z; de Zárraga Fernández MA; Samperiz Abad G; Jarrín I;
J Int AIDS Soc; 2021 Jul; 24(7):e25758. PubMed ID: 34291580
[TBL] [Abstract][Full Text] [Related]
19. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
Hocqueloux L; Raffi F; Prazuck T; Bernard L; Sunder S; Esnault JL; Rey D; Le Moal G; Roncato-Saberan M; André M; Billaud E; Valéry A; Avettand-Fènoël V; Parienti JJ; Allavena C;
Clin Infect Dis; 2019 Oct; 69(9):1498-1505. PubMed ID: 30601976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]